Tirzepatide Cuts Obstructive Sleep Apnea Episodes, Study Review Finds

Obstructive sleep apnea—the most common sleep-related breathing disorder—is characterized by repeated pauses and resumptions of breathing during the night, often accompanied by loud snoring, according to the British newspaper Daily Mail.

Key findings from tirzepatide trials

Researchers at the University of Pittsburgh Medical Center analyzed outcomes from studies examining the link between weight-loss medications and obstructive sleep apnea. Their review included two trials involving 469 patients diagnosed with moderate-to-severe obstructive sleep apnea who received tirzepatide.

Participants lost approximately one-fifth of their body weight. Concurrently, they experienced marked improvement in apnea symptoms. Average apnea-hypopnea index scores dropped by more than 20 events per hour—indicating substantially improved nocturnal breathing and reduced snoring.

Complete remission of obstructive sleep apnea—defined as fewer than five apnea-hypopnea events per hour—was observed in 42% to 50% of those treated with tirzepatide. This rate is roughly three times higher than the remission rate recorded among participants receiving placebo.

Publication and proposed mechanism

The review’s findings were published in JAMA Otolaryngology–Head and Neck Surgery. Investigators hypothesize that weight loss is the primary driver behind the observed improvements.

Excess weight is known to exacerbate obstructive sleep apnea: fat accumulation around the neck can narrow the upper airway, increasing the likelihood of collapse during sleep. Additionally, increased body mass makes lung expansion more difficult.

Clinical context and limitations

Despite these results, researchers emphasize that weight-loss medications—including tirzepatide—are not substitutes for continuous positive airway pressure (CPAP) devices, especially in severe cases. CPAP machines deliver a steady stream of air through a mask to keep the airway open during sleep.

Uncertainty remains regarding whether apnea symptoms may recur after discontinuing tirzepatide, given the documented tendency for weight regain following cessation of GLP-1–based therapies.

In December 2024, U.S. health authorities approved tirzepatide for treating obstructive sleep apnea in adults with obesity. The drug remains unapproved for this indication in the United Kingdom.